Vicore Pharma expands recruitment base for the ATTRACT study
Gothenburg, June 23, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the ATTRACT VP01 (C21) COVID-19 study has been approved by the health authorities in India.In order to accelerate recruitment in the ATTRACT study, Vicore Pharma has performed a thorough review to assess feasibility in countries outside UK and has filed a clinical trial application in India that was approved in record time. “Speed is of the essence in COVID-19, and India still has a steady increase in the number of